Jennifer Gillis, NP
Primary Care · Columbia, SCNPI 1407195688
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 116 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations.
Across 116 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$295
- Novo Nordisk$288
- Dexcom, Inc.$274
- AstraZeneca$178
- Pfizer$145
- AbbVie$129
- plus $762 from 22 others
What the payments were for
- Food & beverage$2,05899%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 19 | $295 |
| Novo Nordisk | 17 | $288 |
| Dexcom, Inc. | 8 | $274 |
| AstraZeneca | 12 | $178 |
| Pfizer | 7 | $145 |
| AbbVie | 8 | $129 |
| Abbott | 5 | $113 |
| Amgen(2 entities) | 7 | $111 |
| Boehringer Ingelheim | 6 | $96 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $63 |
| Novartis | 3 | $55 |
| Zimmer Biomet | 1 | $38 |
| Edwards Lifesciences | 2 | $31 |
| Bayer | 2 | $29 |
| Exact Sciences | 2 | $28 |
| Gilead | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $18 |
| GSK | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Merck | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Inari Medical, Inc. | 1 | $13 |
| Halozyme Inc | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
How this compares
$2,072 in reported general payments places this provider in the 75th percentile of 115 primary care providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $69,074 |
| JardianceEmpagliflozin | 44 | $33,617 |
| FarxigaDapagliflozin Propanediol | 30 | $21,342 |
| EliquisApixaban | 15 | $19,860 |
| MyrbetriqMirabegron | 31 | $18,157 |
| JanuviaSitagliptin Phosphate | 13 | $16,312 |
| MounjaroTirzepatide | 11 | $15,132 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 69 | $3,988 |
| Valsartan | 103 | $3,807 |
| Rosuvastatin Calcium | 84 | $2,773 |
| Levothyroxine Sodium | 157 | $2,467 |
| Atorvastatin Calcium | 152 | $2,403 |
| SynthroidLevothyroxine Sodium | 33 | $2,368 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 14 | $1,926 |
| Losartan Potassium | 103 | $1,901 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $288 | $69,07462 claims |
| Boehringer IngelheimJardiance | $96 | $33,61744 claims |
| AstraZenecaFarxiga | $178 | $21,34230 claims |
| PfizerEliquis, Paxlovid | $145 | $21,28926 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $18,15731 claims |
| MerckJanuvia | $14 | $16,31213 claims |
| Lilly USA, LLCMounjaro | $295 | $15,13211 claims |
| AbbVieSynthroid | $129 | $2,36833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 115 primary care providers in South Carolina.
Other primary care in Columbia
- Patricia HeadColumbia$6K
- Lyndsey MathiasColumbia$3K
- Yolanda Boyd-GanttColumbia$3K
- Madeline SmithColumbia$2K
- Marisa GentryColumbia$2K
- Hadyn GauseColumbia$2K
- Adrenna JacksonColumbia$2K
- Mollie CottyColumbia$2K
- Deidra WillisColumbia$1K
- Tiffany JohnsonColumbia$787
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.